<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561921</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO 3-7-1(18/9/20)</org_study_id>
    <nct_id>NCT04561921</nct_id>
  </id_info>
  <brief_title>Effect of Magnesium Sulphate Added to Mepivacaine Hydrochloride on Inferior Alveolar Nerve Block Success in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars: A Randomized Clinical Trial.</brief_title>
  <official_title>Effect of Magnesium Sulphate Added to Mepivacaine Hydrochloride on Inferior Alveolar Nerve Block Success in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars: A Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study is conducted to assess the effect of adding magnesium sulphate to mepivacaine HCl&#xD;
      compared to mepivacaine HCl alone on the success of inferior alveolar nerve block in patients&#xD;
      with symptomatic irreversible pulpitis in mandibular molars&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 22, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>success of inferior alveolar nerve block measured using a numerical rating scale (NRS)</measure>
    <time_frame>15 minutes after injection</time_frame>
    <description>Intensity of pain 15 minutes after injection during access cavity and initial file placement is recorded by the patient using a numerical rating scale(where 0= no pain ,1-3 =mild pain ,4-6= moderate pain and 7-9= severe pain )</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Success of Inferior Alveolar Nerve Block</condition>
  <arm_group>
    <arm_group_label>megnesium sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 1.8 mL of an anaesthetic solution containing 1% magnesium sulphate , and 1.8% mepivacaine HCL with .06mg Levonordefrin HCl during inferior alveolar nerve block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mepivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 1.8 mL of a local anaesthetic solution containing 1.8% mepivacaine HCL with .06mg Levonordefrin HCL during inferior alveolar nerve block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe</description>
    <arm_group_label>megnesium sulphate</arm_group_label>
    <other_name>magnisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepivacaine-Levonordefrin Hydrochloride</intervention_name>
    <description>patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe</description>
    <arm_group_label>mepivacaine HCl</arm_group_label>
    <other_name>Mepecaine - L</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-55 years old.&#xD;
&#xD;
          2. Systemically healthy patient (ASA I or II).&#xD;
&#xD;
          3. Mandibular molar teeth with:&#xD;
&#xD;
               -  Preoperative sharp pain.&#xD;
&#xD;
               -  No widening in the periodontal ligament (PDL).&#xD;
&#xD;
               -  Vital response of pulp tissue to cold pulp tester (ethyl chloride spray)1.&#xD;
&#xD;
               -  Fully formed roots.&#xD;
&#xD;
          4. Positive patient's acceptance for participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who had used any type of analgesic medication during the preceding 12 hours&#xD;
             before the treatment.&#xD;
&#xD;
          2. Pregnant or nursing females.&#xD;
&#xD;
          3. Patients having significant systemic disorder (ASA III or IV).&#xD;
&#xD;
          4. Drug abusers and subjects who were on antidepressant medication.&#xD;
&#xD;
          5. Re-treatment cases.&#xD;
&#xD;
          6. Patients with a contraindication for the use of magnesium sulphate or those known to&#xD;
             be allergic to any of the study medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>alaa Ib mekhimar, B.D.S</last_name>
    <phone>01096404006</phone>
    <phone_ext>002</phone_ext>
    <email>alaa.ibrahim.ghazy@gmail.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 26, 2020</last_update_submitted>
  <last_update_submitted_qc>September 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Alaa Ibrahim Ibrahim Ghazy Mekhimar</investigator_full_name>
    <investigator_title>Resident at faculty of dentistry, Cairo University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Nordefrin</mesh_term>
    <mesh_term>Mepivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

